{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=61&q=advanced+solid+tumors", "query": { "q": "advanced solid tumors", "condition": "Cancer", "page": 61 }, "page_size": 10 }, "pagination": { "page": 61, "page_size": 10, "total_count": 5930, "total_pages": 593, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=62&q=advanced+solid+tumors&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=60&q=advanced+solid+tumors&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T02:44:47.870Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06759649", "title": "A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm", "Cancer, Malignant Tumors" ], "interventions": [ { "name": "COM503", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Compugen Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2025-01-07", "completion_date": "2027-11-22", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-20T02:44:47.870Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Grand Rapids, Michigan + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Germantown", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06759649" }, { "nct_id": "NCT07337525", "title": "A First in Human Study of PLT012 in Participants With Solid Tumor Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Tumor", "Solid Tumor Cancer" ], "interventions": [ { "name": "PLT012", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pilatus Biosciences Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2026-02-13", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-20T02:44:47.870Z", "location_count": 4, "location_summary": "Los Angeles, California • Dallas, Texas • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07337525" }, { "nct_id": "NCT00705874", "title": "Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "CGC-11047 and gemcitabine", "type": "DRUG" }, { "name": "CGC-11047 and docetaxel", "type": "DRUG" }, { "name": "CGC-11047 and bevacizumab", "type": "DRUG" }, { "name": "CGC-11047 and erlotinib", "type": "DRUG" }, { "name": "CGC-11047 and cisplatin", "type": "DRUG" }, { "name": "CGC-11047 and 5-flurouracil / leucovorin", "type": "DRUG" }, { "name": "CGC-11047 and sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Progen Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 172, "start_date": "2006-05", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2016-07-21", "last_synced_at": "2026-10-20T02:44:47.870Z", "location_count": 12, "location_summary": "Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 9 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Ocoee", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Albany", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00705874" }, { "nct_id": "NCT04780217", "title": "Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Hepatocellular Carcinoma", "Colorectal Cancer", "NSCLC", "Ovarian Cancer", "Endometrial Cancer" ], "interventions": [ { "name": "T3011", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ImmVira Pharma Co. Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2021-08-10", "completion_date": "2025-08", "has_results": false, "last_update_posted_date": "2024-03-04", "last_synced_at": "2026-10-20T02:44:47.870Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Plantation, Florida • Greenville, South Carolina + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Plantation", "state": "Florida" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04780217" }, { "nct_id": "NCT06234397", "title": "Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "BH3120", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hanmi Pharmaceutical Company Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 216, "start_date": "2023-12-28", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-20T02:44:47.870Z", "location_count": 5, "location_summary": "Tampa, Florida • Grand Rapids, Michigan • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06234397" }, { "nct_id": "NCT03463460", "title": "Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thymic Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sunitinib Malate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "Dwight Owen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2018-06-19", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-20T02:44:47.870Z", "location_count": 3, "location_summary": "Tampa, Florida • Indianapolis, Indiana • Columbus, Ohio", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03463460" }, { "nct_id": "NCT01957280", "title": "Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "patritumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2013-06", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2014-05-14", "last_synced_at": "2026-10-20T02:44:47.870Z", "location_count": 3, "location_summary": "Tampa, Florida • Oklahoma City, Oklahoma • San Antonio, Texas", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01957280" }, { "nct_id": "NCT00298779", "title": "Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors", "Non-Hodgkins's Lymphoma" ], "interventions": [ { "name": "omeprazole and bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2008-06-06", "last_synced_at": "2026-10-20T02:44:47.870Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00298779" }, { "nct_id": "NCT04849273", "title": "A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Non-Small Cell Lung Cancer", "NSCLC", "Advanced Solid Tumor", "Metastatic Solid Tumor", "ALK Gene Mutation" ], "interventions": [ { "name": "TPX-0131", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Turning Point Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2021-07-28", "completion_date": "2023-04-18", "has_results": false, "last_update_posted_date": "2023-05-26", "last_synced_at": "2026-10-20T02:44:47.870Z", "location_count": 7, "location_summary": "Orange, California • Aurora, Colorado • Boston, Massachusetts + 3 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04849273" }, { "nct_id": "NCT06242470", "title": "A Study of MGC026 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Advanced Cancer", "Metastatic Cancer", "Squamous Cell Carcinoma of Head and Neck", "Non Small Cell Lung Cancer", "Small-cell Lung Cancer", "Bladder Cancer", "Sarcoma", "Endometrial Cancer", "Melanoma", "Castration Resistant Prostatic Cancer", "Cervical Cancer", "Colorectal Cancer", "Gastric Cancer", "Gastro-esophageal Cancer", "Pancreas Cancer", "Clear Cell Renal Cell Carcinoma", "Hepatocellular Carcinoma", "Platinum-resistant Ovarian Cancer", "Breast Cancer", "Ovarian Cancer", "Esophageal Squamous Cell Cancer (SCC)" ], "interventions": [ { "name": "MGC026 Dose Escalation", "type": "BIOLOGICAL" }, { "name": "MGC026 Dose for Expansion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2024-03-06", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-20T02:44:47.870Z", "location_count": 7, "location_summary": "Los Angeles, California • Grand Rapids, Michigan • Lake Success, New York + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06242470" } ] }